avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

6mo

VSTMPhase 2$540M

avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel Phase 2 Results Expected

avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel• KRAS Activating Mutation40

Aug 31Estimated

00%

Competitive Landscape

0 competitors in KRAS Activating Mutation

Drug Information

Target Indication

KRAS Activating Mutation

Clinical Trial

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

VSTM

Verastem, Inc.

Related Pipeline

Low Grade Serous Ovarian Cancer

Low Grade Ovarian Serous Adenocarcinoma

Low Grade Serous Ovarian Cancer

Non Small Cell Lung Cancer

Non Small Cell Lung Cancer